Certara (NASDAQ:CERT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Certara (NASDAQ:CERT) from a hold rating to a buy rating in a research note published on Monday morning.

Several other analysts have also weighed in on CERT. Rothschild & Co Redburn initiated coverage on Certara in a research note on Friday, November 21st. They issued a “buy” rating and a $10.00 price objective on the stock. UBS Group reduced their price target on shares of Certara from $17.50 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Barclays lowered their price objective on shares of Certara from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Friday, November 7th. BMO Capital Markets initiated coverage on shares of Certara in a research note on Thursday, November 13th. They issued a “market perform” rating and a $9.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a research note on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.82.

Certara Stock Performance

NASDAQ CERT opened at $9.14 on Monday. The firm’s 50 day simple moving average is $11.16 and its 200 day simple moving average is $11.08. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 130.57 and a beta of 1.44. The company has a current ratio of 2.09, a quick ratio of 2.09 and a debt-to-equity ratio of 0.27. Certara has a 1 year low of $8.02 and a 1 year high of $15.69.

Certara (NASDAQ:CERT) last released its earnings results on Thursday, November 6th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.03. The firm had revenue of $104.62 million during the quarter, compared to analysts’ expectations of $104.53 million. Certara had a return on equity of 5.18% and a net margin of 2.62%.During the same period in the prior year, the company earned $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. As a group, research analysts expect that Certara will post 0.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction dated Tuesday, September 9th. The stock was sold at an average price of $10.92, for a total transaction of $559,366.08. Following the completion of the transaction, the insider directly owned 73,979 shares in the company, valued at $807,850.68. This trade represents a 40.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.33% of the company’s stock.

Institutional Trading of Certara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CERT. AdvisorNet Financial Inc acquired a new position in shares of Certara in the 2nd quarter worth approximately $25,000. First Horizon Corp bought a new position in Certara during the third quarter worth $30,000. Caitong International Asset Management Co. Ltd bought a new position in Certara during the first quarter worth $31,000. Versant Capital Management Inc lifted its holdings in Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after buying an additional 1,153 shares during the period. Finally, AlphaQuest LLC bought a new stake in Certara during the first quarter valued at $39,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.